Delcath Systems, Inc. (DCTH) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Seven analysts assign Delcath Systems a “Moderate Buy” consensus, with five buys and two holds. The average 12-month price target is $23.17, above the stock’s reported $15.67 price.
• Delcath reported quarterly EPS of $0.07, beating the consensus estimate of a $0.09 loss, while revenue of $29.13 million also exceeded expectations of $26.25 million. Analysts nevertheless expect a full-year loss of $0.17 per share.
• Institutional ownership stands at 61.12%: Several investment firms recently initiated or increased positions, including Bank of America, Royal Bank of Canada, and Bank of New York Mellon.

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.17.

DCTH has been the topic of several research reports. Zacks Research lowered Delcath Systems from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 6th. BTIG Research raised their price target on Delcath Systems from $17.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. HC Wainwright reiterated a "buy" rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Wall Street Zen raised Delcath Systems from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised Delcath Systems from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, September 28th.

Delcath Systems Trading Up 2.0%

NASDAQ DCTH opened at $15.67 on Tuesday. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $17.42. The firm's fifty day simple moving average is $16.08 and its 200-day simple moving average is $13.04. The company has a market capitalization of $543.75 million, a PE ratio of 1,568.57 and a beta of 0.60.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.16. The firm had revenue of $29.13 million during the quarter, compared to analysts' expectations of $26.25 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. As a group, analysts predict that Delcath Systems will post -0.17 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in shares of Delcath Systems during the 2nd quarter worth $1,362,000. Integrated Wealth Concepts LLC bought a new position in shares of Delcath Systems during the 2nd quarter valued at $48,000. IFP Advisors Inc acquired a new stake in shares of Delcath Systems in the 2nd quarter valued at $52,000. Bank of America Corp DE lifted its stake in shares of Delcath Systems by 54.0% in the 1st quarter. Bank of America Corp DE now owns 57,729 shares of the company's stock valued at $536,000 after purchasing an additional 20,249 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Delcath Systems by 14.8% in the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company's stock valued at $170,000 after purchasing an additional 2,364 shares during the last quarter. Institutional investors own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc is a commercial-stage oncology company focused on liver-directed therapies for patients with metastatic cancer. Its technology is designed to deliver high concentrations of chemotherapy directly to the liver while limiting systemic exposure, addressing cancers that are difficult to treat with conventional approaches.

The company's primary products are HEPZATO (melphalan for injection) and the HEPZATO KIT in the United States, as well as CHEMOSAT in markets outside the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.